Home > Haematology > EHA 2021 > EHA 2021 Highlights Podcast

EHA 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
EHA 2021
  In this episode, Medicom’s correspondent covers 5 presentations from the European Haematology Association (EHA), held 9-17 June 2021. The topics discussed are: ELEVATE-TN 4-year follow-up: Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia. Immuno-oncology agents effective in treating classic Hodgkin's lymphoma. GLOW trial: Fixed-duration ibrutinib + venetoclax was a superior treatment in older or unfit patients with chronic lymphocytic leukaemia compared with chlorambucil + obinutuzumab. These data support the positive clinical profile of all-oral, once-daily, fixed-duration ibrutinib plus venetoclax as first-line treatment for this patient population. In patients with newly diagnosed multiple myeloma, daratumumab with standard-of-care (i.e. lenalidomide and dexamethasone) achieved superior outcomes in OS, PFS and ORR com...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on